Nalbuphine as a Potential Alternative to Morphine in Sickle Cell Disease Patients with Vaso-occlusive Crisis: A Retrospective Cohort Study.

Saudi J Med Med Sci · 2025 · PMC12366906 · PMID 40843224

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantP = 0.00002actually significant

By 24 hours, the difference was highly significant ( P = 0.00002), with 30% and 40% of patients on nalbuphine experiencing no or mild pain compared with 15% and 25% of patients in the morphine group, respectively.

also in 132,142 other papers

showed a trendno p-value reported

At 1 h, nalbuphine showed a trend toward more patients reporting “no pain,” but this difference was not significant ( P = 0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.